Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Imunon ( (IMNN) ).
On December 29, 2025, Imunon entered into a securities purchase agreement with a single healthcare-focused institutional investor for a registered direct offering of common shares or pre-funded warrants, together with warrants, priced at-the-market under Nasdaq rules and expected to close around December 31, 2025, raising approximately $7.0 million in gross proceeds. The financing, supported by Maxim Group as lead placement agent and Brookline Capital Markets as co-placement agent, is intended to fund general corporate purposes including research and development, capital expenditures and working capital, with lock-up agreements by officers and directors for 60 days after closing, underscoring the company’s ongoing capital-raising efforts to support its Phase 3 immunotherapy program and broader development pipeline.
The most recent analyst rating on (IMNN) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, sustained losses, and ongoing negative free cash flow driving financing/dilution risk) and bearish technicals (price below major moving averages with negative MACD). The earnings call provides a partial offset due to positive trial/regulatory progress and meaningful cost reductions, but near-term cash runway remains a key risk.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
Imunon, Inc. is a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapies and other treatments that harness the body’s natural mechanisms to produce safe, effective and durable responses across a wide range of human diseases, positioning it as an innovator in alternative approaches to conventional therapies.
Average Trading Volume: 66,258
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.15M
Learn more about IMNN stock on TipRanks’ Stock Analysis page.